RLYB PE Ratio & Valuation, Is RLYB Overvalued

Historical Valuation

Rallybio Corp (RLYB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 224.15 is considered Overvalued compared with the five-year average of -2.35. The fair price of Rallybio Corp (RLYB) is between 1.28 to 8.62 according to relative valuation method. Compared to the current price of 10.91 USD , Rallybio Corp By Overvalued By 26.63%.

Relative Value

Fair Zone

1.28-8.62

Current Price：10.91

26.63%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Rallybio Corp (RLYB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Rallybio Corp (RLYB) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 0.74, the current P/B ratio is approximately -36.51% higher. Relative to its 5-year average P/B ratio of 1.09, the current P/B ratio is about -56.71% higher. Rallybio Corp (RLYB) has a Forward Free Cash Flow (FCF) yield of approximately -117.13%. Compared to its 3-year average FCF yield of -117.11%, the current FCF yield is approximately 0.02% lower. Relative to its 5-year average FCF yield of -79.70%, the current FCF yield is about 46.96% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RLYB competitors is 45.76, providing a benchmark for relative valuation. Rallybio Corp Corp (RLYB.O) exhibits a P/S ratio of 224.15, which is 389.85% above the industry average. Given its robust revenue growth of -29.10%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RLYB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RLYB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RLYB currently overvalued or undervalued?

What is Rallybio Corp (RLYB) fair value?

RLYB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Rallybio Corp (RLYB) is between 1.28 to 8.62 according to relative valuation method.

How does RLYB's valuation metrics compare to the industry average?

The average P/S ratio for RLYB's competitors is 45.76, providing a benchmark for relative valuation. Rallybio Corp Corp (RLYB) exhibits a P/S ratio of 224.15, which is 389.85% above the industry average. Given its robust revenue growth of -29.10%, this premium appears unsustainable.

What is the current P/B ratio for Rallybio Corp (RLYB) as of Mar 10 2026?

As of Mar 10 2026, Rallybio Corp (RLYB) has a P/B ratio of 0.47. This indicates that the market values RLYB at 0.47 times its book value.

What is the current FCF Yield for Rallybio Corp (RLYB) as of Mar 10 2026?

As of Mar 10 2026, Rallybio Corp (RLYB) has a FCF Yield of -117.13%. This means that for every dollar of Rallybio Corp's market capitalization, the company generates -117.13 cents in free cash flow.

What is the current Forward P/E ratio for Rallybio Corp (RLYB) as of Mar 10 2026?

As of Mar 10 2026, Rallybio Corp (RLYB) has a Forward P/E ratio of -1.11. This means the market is willing to pay $-1.11 for every dollar of Rallybio Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Rallybio Corp (RLYB) as of Mar 10 2026?

As of Mar 10 2026, Rallybio Corp (RLYB) has a Forward P/S ratio of 224.15. This means the market is valuing RLYB at $224.15 for every dollar of expected revenue over the next 12 months.

RLYB Valuation